We determined whether low bilirubin level is a risk factor for peripheral arterial disease (PAD). We recruited 318 patients with PAD and 100 healthy volunteers. Patients were divided into 4 groups by the Fontaine classification for PAD, namely, group 1 (grade 1, n = 4); group 2 (grade 2, n = 114), group 3 (grade 3, n = 164), and group 4 (grade 4, n = 36). Total bilirubin (T-BIL), direct bilirubin (D-BIL), and indirect bilirubin (I-BIL) levels were compared using stepwise multiple regressions adjusted for selected factors. After adjusting for gender, age, smoking, and diastolic blood pressure, serum levels of T-BIL, D-BIL, and I-BIL were significantly lower in the PAD group (P < .05). Patients with grade 4 PAD showed significantly (P < .05) lower levels of T-BIL when compared with grade 2 patients. We concluded that serum bilirubin levels are negatively correlated with the severity and progression of PAD.
FujiwaraTSaitohSTakagiS. Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. Atherosclerosis. 2004;177(1):83–88.
2.
MutiranguraPRuangsetakitCWongwanitCSermsathanasawadiNChinsakchaiK. Atherosclerosis obliterans of the lower extremities in Thai patients. J Med Assoc Thai. 2006;89(10):1612–1620.
3.
NorgrenLHiattWRDormandyJANehlerMRHarrisKAFowkesFGRutherfordRB; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Int Angiol.2007;26(2):81-157. Review.
4.
SchwertnerHAJacksonWGTolanG. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994;40(1):18–23.
5.
BreimerLHSpyropolousKAWinderAFMikhailidisDPHamiltonG. Is bilirubin protective against coronary artery disease?Clin Chem. 1994;40(10):1987–1988.
6.
KrijgsmanBPapadakisJAGanotakisESMikhailidisDPHamiltonG. The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int Angiol. 2002;21(1):44–52.
7.
NovotnýLVítekL. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood). 2003;228(5):568–571.
8.
VítekLNovotnýLSperlMHolajRSpácilJ. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis. 2006;21(5-6):408–414.
9.
PerlsteinTSPandeRLBeckmanJACreagerMA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol. 2008;28(1):166–172.
10.
HuntSCKronenbergFEckfeldtJHHopkinsPNMyersRHHeissG. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis. 2001;154(3):747–754.
11.
RantnerBKolleritsBAnderwald-StadlerM. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin Chem. 2008;54(5):851–857.
12.
SchwertnerHAVítekL. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis. 2008;198(1):1–11.
13.
TroughtonJAWoodsideJVYoungIS. PRIME Study Group. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil. 2007;14(1):79–84.
14.
OhnakaKKonoSInoguchiT. Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res Clin Pract. 2010;88(1):103–110.
15.
WuTWFungKPWuJYangCCWeiselRD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol. 1996;51(6):859–862.
16.
YangJJChengYTZhangJH. The relationship between bilirubin and oxygen free radicals and cardiovascular diseases. Chin J Arteriosclerosis. 2006;14:53–56.
17.
GulluHErdoganDTokD. High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions. Arterioscler Thromb Vasc Biol. 2005;25(11):2289–2294.
18.
LingenhelAKolleritsBSchwaigerJP. Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease. Exp Gerontol. 2008;43(12):1102–1107.
19.
SuematsuMIshimuraY. The heme oxygenase-carbon monoxide system: a regulator of hepatobiliary function. Hepatology. 2000;31(1):3–6.
20.
BreimerLHMikhailidisDP. Could carbon monoxide and bilirubin be friends as well as foes of the body?Scand J Clin Lab Invest. 2010;70(1):1–5.
21.
OllingerRBilbanMEratA. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation. 2005;112(7):1030–1039.
22.
VicenteAMGuillinMIAlcarazMJ. Participation of heme oxygenase-1 in a model of acute inflammation. Exp Biol Med (Maywood). 2003;228(5):514–516.
23.
PaineAEiz-VesperBBlasczykRImmenschuhS. Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol. 2010;80(12):1895–1803.
24.
EkblomKMarklundSLJohanssonL. Bilirubin and UGT1A1*28 are not associated with lower risk for ischemic stroke in a prospective nested case-referent setting. Cerebrovasc Dis. 2010;30(6):590–596.
25.
EkblomKMarklundSLJanssonJH. Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting. Circ Cardiovasc Genet. 2010;3(4):340–347.
26.
PossKDTonegawaS. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci U S A. 1997;94(20):10925–10930.
27.
NakayamaMTakahashiKKomaruT. Increased expression of heme oxygenase l and bilirubin accumulation in foam cells of rabbit atherosclerotic lesions. Arteroscler Thromb Vasc Biol. 2001;21(8):1373–1377.
28.
AmitYBonehA. Bilirubin inhibits protein kinase C activity and protein kinase C-mediated phosphorylation of endogenous substrates in human skin fibroblasts. Clin Chim Acta. 1993;223(1-2):103–111.
29.
ZouTYangWHouZYangJ. Homocysteine enhances cell proliferation in vascular smooth muscle cells: role of p38 MAPK and p47phox. Acta Biochim Biophys Sin (Shanghai). 2010;42(12):908–915.
